GRI Bio
1 hedge funds and large institutions have $5.09M invested in GRI Bio in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
36,109% more capital inflows, than outflows
Capital inflows: $8.89M | Capital outflows: $24.6K
40.24% more ownership
Funds ownership: 0.77% → 41.02% (+40%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$8.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Securities
New York
|
-$8.21K |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.84K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.46K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.01K |
| 5 |
Archer Investment Corporation
Carmel,
Indiana
|
-$36 |
GRI Hedge Fund Activity: Q2 2023 in Review
1 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in GRI Bio (GRI) for Q2 2023, worth a combined $5.09M — up 13,496% from $37.4K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new GRI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $8.89M. The largest seller was Two Sigma Securities, cutting an estimated $8.21K.
- 1 institutional investor held GRI Bio (GRI) as of Q2 2023, up from 0 in Q1 2023.
- Funds reported $5.09M of GRI Bio stock for Q2 2023, up 13,496% quarter-over-quarter.
- 1 fund opened new GRI Bio positions in Q2 2023 and 0 closed out, a net change of +1 holder.
- The largest GRI Bio buyer in Q2 2023 was Altium Capital Management, an estimated $8.89M added.
- The largest GRI Bio seller in Q2 2023 was Two Sigma Securities, an estimated $8.21K sold.
Based on aggregated 13F filings for Q2 2023.